Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 17:57 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Effects of Prolonged Delivery of Nitric Oxide Gas on Plasma Reduction-Oxidation Reactions in Cardiac Surgical Patients
NCT04022161 · Massachusetts General Hospital · PHASE2 · withdrawn · last registry update 2025-12-02 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Lack of funding” | – | Registry record, Massachusetts General Hospital |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against GUCY1B1 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2026-10-29Also stopped (withdrawn): Anna Stanhewicz, PhD, Eplerenone (NCT07345845)
- 2026-10-13Also stopped (terminated): Beyond Air Inc., Nitric Oxide 25,000 ppm + Nitric Oxide 50,000 ppm (NCT05351502)
- 2026-09-03Also stopped (terminated): Dr Sudarshan Rajagopal, Macitentan Tablets + Riociguat (NCT05140525)
- 2026-08-20Also stopped (terminated): Bayer, Riociguat (Adempas, BAY63-2521) + Riociguat (Adempas, BAY63-2521) (NCT01065454)
- 2026-08-12Phase 3 first posted: Khon Kaen University, Botulinum toxin A via microneedle (NCT07759557)
- 2026-06-17Results posted on the registry: Heidelberg University, Riociguat (NCT04954742)
- 2026-06-17Also stopped (terminated): Heidelberg University, Riociguat (NCT04954742)
- 2026-06-12Phase 3 first posted: Assistance Publique - Hôpitaux de Paris, Discontinuation of riociguat (NCT07644377)
- 2026-04-09Results posted on the registry: The Methodist Hospital Research Institute, L-NMMA + Pembrolizumab (NCT03236935)
- 2026-04-01Results posted on the registry: Massachusetts General Hospital, Nitric Oxide Gas (NCT04306393)
- 2026-03-23Results posted on the registry: Massachusetts General Hospital, Nitric Oxide (NCT04305457)
- 2026-03-23Also stopped (terminated): Massachusetts General Hospital, Nitric Oxide (NCT04305457)
- 2026-03-20Results posted on the registry: Massachusetts General Hospital, Inhaled nitric oxide gas (NCT04312243)
- 2026-03-20Also stopped (terminated): Massachusetts General Hospital, Inhaled nitric oxide gas (NCT04312243)
- 2026-03-18Also stopped (suspended): Instituto Nacional de Cardiologia Ignacio Chavez, Nitroglycerin 100 MCG/ML Injectable Solution + Saline Solution (NCT03304496)
- 2026-03-18Also stopped (withdrawn): University of California, Los Angeles, inhaled nitric oxide (iNO) (NCT04996667)
- 2026-03-10Results posted on the registry: Massachusetts General Hospital, Nitric Oxide (NCT02836899)
- 2026-03-10Results posted on the registry: CVRx, Inc., Medical Management (NCT02627196)
- 2026-02-27Results posted on the registry: Penn State University, Acetylcholine + Sodium Nitroprusside (NCT03953326)
- 2026-02-27Also stopped (terminated): Penn State University, Acetylcholine + Sodium Nitroprusside (NCT03953326)
- 2026-01-27Results posted on the registry: Johns Hopkins University, Vericiguat + Placebo (NCT05711719)
- 2026-01-21Results posted on the registry: Heidelberg University, Riociguat Oral Tablet (NCT05339087)
- 2026-01-21Also stopped (terminated): Heidelberg University, Riociguat Oral Tablet (NCT05339087)
- 2025-12-30Also stopped (terminated): Beth Israel Deaconess Medical Center, Sodium Nitroprusside + 5% Dextrose solution (NCT04986072)
- 2025-12-19Results posted on the registry: Merck Sharp & Dohme LLC, Vericiguat + Placebo (NCT05093933)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision